Although the anti-tumor activity is reduced in the case of low-affinity EpCAM CARs, we showed in GC models that supplementing affinity-tuned CAR-T cells with NFAT-inducible IL-12 expression can result in durable remission of advanced tumors that are not responsive to affinity-tuned CAR-T cells alone. Here, EPCAM is linked to neoplasm.